Publication | Closed Access
Phase I Study of Recombinant Human CD40 Ligand in Cancer Patients
224
Citations
34
References
2001
Year
The MTD of rhuCD40L when administered subcutaneously daily for 5 days was defined by transient serum elevations in hepatic transaminases. Encouraging antitumor activity, including a long-term complete remission, was observed. Phase II studies are warranted.
| Year | Citations | |
|---|---|---|
Page 1
Page 1